Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons
Article first published online: 15 MAY 2013
© 2013 International Society for Neurochemistry
Journal of Neurochemistry
Volume 126, Issue 5, pages 685–695, September 2013
How to Cite
J. Neurochem. (2013) 126, 685–695.
- Issue published online: 23 AUG 2013
- Article first published online: 15 MAY 2013
- Accepted manuscript online: 13 APR 2013 08:25AM EST
- Manuscript Accepted: 10 APR 2013
- Manuscript Revised: 11 MAR 2013
- Manuscript Received: 13 NOV 2012
- World Class University (WCU)
- Ministry of Education
- Science and Technology. Grant Number: R33-2008-000-10090-0
Figure S1. Troglitazone does not alter the phosphorylation states of tau at other sites such as Thr212, Ser262, and Ser396 in SH-SY5Y cells.
Figure S2. Roscovitine, a CDK5 inhibitor, further decreases tau-Thr231 phosphorylation and p35 expression remained in the troglitazone-treated SH-SY5Y cells.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.